Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Not yet recruiting2
Completed2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

unknown117%
not_yet_recruiting233%
terminated117%
completed233%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

NCT05521997
not_yet_recruitingphase_1

TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

NCT07223528
terminatedphase_2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534
unknownphase_2

Telaglenastat + Talazoparib In Prostate Cancer

NCT04824937
completedphase_1

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

NCT04607512
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05521997Phase 2

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Not Yet Recruiting
NCT07223528Phase 1

TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

Not Yet Recruiting
NCT04265534Phase 2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Terminated
NCT04824937Phase 2

Telaglenastat + Talazoparib In Prostate Cancer

Unknown
NCT04607512Phase 1

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

Completed
NCT04540965Phase 1

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6